PF-04859989

a potent, brain-penetrant inhibitor of kynurenine aminotransferase II/KAT II with in vivo activity; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Gritton, Howard: 1 article (07/2014)
2.	Johnson, David E: 1 article (07/2014)
3.	Koshy Cherian, Ajeesh: 1 article (07/2014)
4.	Kozak, Rouba: 1 article (07/2014)
5.	Sarter, Martin: 1 article (07/2014)
6.	Young, Damon: 1 article (07/2014)

1.	Cognitive Dysfunction 01/01/2022 - "By using the selective, brain-penetrable KAT II inhibitor PF-04859989, we then examined whether blockade of KYNA neosynthesis prevents the cognitive impairment. " 01/01/2022 - "Chronic adolescent THC exposure negatively affected short-term memory (reduced spontaneous alternation), in adult animals (p < 0.001), while PF-04859989 (30 mg/kg i.p.) restored the cognitive impairment (p < 0.05). "
2.	Neurobehavioral Manifestations 07/01/2014 - "Because PF-04859989 restores evoked glutamate signaling it therefore is a promising therapeutic compound for benefiting the cognitive symptoms of schizophrenia and other disorders associated with elevated brain KYNA levels."
3.	Schizophrenia (Dementia Praecox) 07/01/2014 - "Because PF-04859989 restores evoked glutamate signaling it therefore is a promising therapeutic compound for benefiting the cognitive symptoms of schizophrenia and other disorders associated with elevated brain KYNA levels."